Ten-Indication Phase II and Phase III Empirical Baseline (2018 to 2026)
Every Protocol Ledger study reconciles raw ClinicalTrials.gov v2 facility tuples, M&A subsidiary lineages, and date-horizon anomalies before computing completion and duration benchmarks for the Sponsor & Site Directory.
| Code | Therapeutic Area | Protocols | Completed | Stopped | Stop % | Median N | Median Days |
|---|---|---|---|---|---|---|---|
| ONC | Oncology and Hematology | 22,601 | 3,040 | 2,734 | 12.10% | 43.0 | 1,269 |
| OTH | Rare Genetic, Women's Health, and Other | 10,777 | 3,957 | 1,190 | 11.04% | 60.0 | 572 |
| INF | Infectious Disease and Vaccines | 5,536 | 2,510 | 933 | 16.85% | 152.0 | 456 |
| NEU | Neurology, Psychiatry, and Pain | 4,809 | 1,763 | 628 | 13.06% | 84.0 | 714 |
| IMM | Immunology, Rheumatology, and Dermatology | 3,376 | 1,249 | 466 | 13.80% | 119.0 | 690 |
| END | Endocrinology, Obesity, and Metabolic | 2,382 | 1,032 | 219 | 9.19% | 113.0 | 616 |
| CVM | Cardiovascular and Thrombosis | 2,184 | 799 | 245 | 11.22% | 102.5 | 695 |
| RSP | Respiratory and Pulmonary | 1,201 | 506 | 146 | 12.16% | 91.0 | 651 |
| GAS | Gastroenterology, Hepatology, and Renal | 1,088 | 396 | 140 | 12.87% | 76.0 | 663 |
| OPH | Ophthalmology and Sensory | 936 | 438 | 95 | 10.15% | 106.0 | 427 |
Related Engineering Notes
Protocol Ledger applies deterministic entity reconciliation across ClinicalTrials.gov v2 and FDA Drugs@FDA archives. For technical background on how Meru AI resolves hospital campuses and biopharma sponsor lineages across federal sources, see Cross-Agency Entity Resolution, Citation-Grade Public Data Architecture, and the broader Meru AI Public Data Platforms overview.